Companies

Entrepreneurship is about how you monetise an idea: Kiran Mazumdar Shaw

Anil Urs Bengaluru | Updated on December 16, 2019 Published on December 16, 2019

Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon Ltd. File photo   -  Bloomberg

Over 3,000 biotech, agri and life sciences companies from across 33 States/Union Territories pitch for funding at C-CAMP’s National Bio Entrepreneurship Competition

“Entrepreneurship is about how you monetise an idea and take it to market. So don’t wait for the perfect idea or wait for that one good idea,” said Dr Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon Ltd.

Addressing the C-CAMP National Bio Entrepreneurship Competition - a nationwide platform for bio-entrepreneurs to showcase their tech business ideas in the Life Sciences and biotech domain, Shaw, said “Shape your ideas and begin the commercialisation journey and scale it up. Because impact and true recognition lie only in scaling.”

She further exhorted entrepreneurs to see their innovation from idea through product stage.

Award winners

Divanshu of Alcheme was awarded the WIN Foundation cash prize of Rs 7.5 lakhs as well as their investment opportunity of Rs 30 lakhs in water and sanitation category. Mayur Shetty of Blackfrog Technologies received the WIN Foundation cash prize of Rs 7.5 lakhs and also the WIN Foundation investment opportunity of Rs 30 lakhs in maternal and child health category.

Blackfrog swooped up the Social Alpha investment opportunity of $100,000 too for their astounding potential for social impact. Ragul Paramasivam of Chimertech Innovations LLP, won the Ankur Seeds award of Rs 5 lakhs in agri-biotech category as well as the ID capital investment opportunity of $100,000 as top agri-biotech, food and nutraceuticals entrepreneur.

Shomeshwar Singh of 4S Medical Research, was awarded the Digital Health cash prize of Rs 5 lakhs sponsored by HealthVenture, USA.

Prakhar Jain of MicroX Labs won the Applied Materials India award of Rs 5lakhs in medtech innovation category.

Rajesh Nandipati of Oncosimis Biotech received the Rs 5 lakhs Excellence Prize sponsored by Biocon.

Asawari Kane of PadCare Labs was awarded the Novozymes Excellence Prize of Rs 3 lakhs.

The Pfizer Entrepreneurship Award of Rs 3.5lakhs went to Arindam Ghatak of Biomoneta.

Halagappa Eswarappa Shashidhar of CultivaAgriTech received the Mahyco cash prize of Rs 1 lakh in Agri-Biotech.

An Investment opportunity of $75,000 from HealthVenture, USA in Digital Health was announced for Rohit Hiwale of Morphle Technologies.

Finally, a special prize from C-CAMP’s end was awarded to Shilpa Malik of Bioscan Research.

Boot camp/mentoring sessions

At the NBEC about 65 start-ups gleaned from over 3,000 registrations across 33 States/UTs had participated in the two-day Boot Camp and Mentoring Sessions with mentors from CIIE - IIM Ahmedabad prior to the finals.

The competition in its third edition had 17 industry partners including international partners from the USA, France and Singapore on board: WIN Foundation, Ankur Seeds, Applied Materials India, Amazon Web Services (AWS), Biocon, CIIE – IIM Ahmedabad, Confederation of Indian Industry (CII), CNBC-TV18 Young Turks, GE, HealthVenture - USA, Hello Tomorrow, ID Capital, Kotak Private Equity, Mahyco, Novozymes, Pfizer, and Social Alpha.

Dr Taslimarif Saiyed, CEO & Director, C-CAMP said, “CCAMP believes that through fostering deep science innovations we have an opportunity to make a major impact in India’s growth. CCAMP is dedicated to play this vital role and looks forward to working together with you towards building tomorrow’s innovations from India.”

Published on December 16, 2019

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.